Key result
Standard HF therapy remains widely underprescribed and underdosed due to therapeutic inertia and physiological limits.
Why the study?
This review evaluates the significance of readmissions for decompensated heart failure, medication use to lower hospitalization risk, and reasons for inadequate prescription and underdosing in heart failure with reduced ejection fraction.
Answers are grounded in this paper and cite their sources.
This review highlights the gap between guideline-directed medical therapy in clinical trials versus real-world practice for HFrEF, emphasizing the need to overcome therapeutic inertia.
This review considers the clinical and epidemiological significance of hospitalizations for decompensated heart failure, as well as using it as an indicator of therapy effectiveness. The data on the frequency of using medications that reduce the hospitalization risk in randomized clinical trials and in real practice are presented. The reasons for inadequate prescription of drugs for the treatment of heart failure with reduced ejection fraction and their use in insufficient doses, which include therapeutic inertness and physiological limitations, as well as the need to introduce drugs with alternative mechanisms of action into clinical practice, are iscussed.
No takes yet. Share an insight, caveat, or question.
S. R. Gilyarevsky (2021) conducted a review in Heart failure with reduced ejection fraction. Standard heart failure therapy was evaluated on Hospitalizations for decompensated heart failure. Standard heart failure therapy is often inadequately prescribed or underdosed in clinical practice due to therapeutic inertness and physiological limitations.
Synapse has enriched 10 related papers. Consider them for comparative context: